Review on AKAP12, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
DNA/RNA
The AKAP12 gene and promoter structure is strongly conserved from fish to humans, including syntenic regions conserved in the mouse (chrom. 10) and rat (chrom. 1). No family members (homologues) other than AKAP12 exist within a given species.
Human and mouse cells have similar exon/intron usage and spacing. AKAP12 has three independent promoters, α, β, and γ. The gamma promoter is active only in the testes while the α and β are co-active in most cells and tissues studied. Exons 1A1 and 1A2 combine to then splice to a common splice acceptor on Exon 2 used by Exon 1B. Exons 1A1 and 1A2 produce the Nterminal 103 amino acids of "AKAP12 alpha" whereas Exon 1B encodes the N-terminal 8 amino acids of "AKAP12 β"; the remaining amino acids are encoded in Exon 2. "AKAP12 gamma" is encoded by a read-through transcript starting in the intron upstream of Exon 2, utilizing an in-frame ATG in Exon 2. Therefore, the α, β, and γ transcripts encode proteins that only differ in their N-termini.
Transcription
Human and rodent AKAP12 is expressed ubiquitously, with greater expression in mesenchymal cells, expression in specific epithelial types, such as breast and prostate, and little in most endothelial cells. Several highly specialized, differentiated cells type, such as parietal cells in the glomerulus, pericytes, astrocytes and Purkinje cells, show especially strong expression.
Pseudogene
None.
Protein
Expression AKAP12 isoforms are expressed in most tissue and organ types, with high expression levels in the testes, ovary, brain, lung and heart. Most mesenchyme, smooth muscle and some epithelial cells (breast, prostate, lung, ovary) express significant AKAP12 levels. Lower levels of AKAP12 are found in endothelial cells, although express in these cells is usually associated with wounding and/or inflammation. High expression is also found in some specialized, differentiated cells such as the parietal cells of the glomerulus, pericytes, astrocytes and Purkinje cells.
Localisation
Most cell types display a cortical cytoskeletal staining pattern for AKAP12, with enrichment at the plasma membrane (associated with N-terminal myristylation and at least three N-terminal polybasic domains) and in the perinucleus. However, some staining has been observed in cell nuclei, probably directed by 4 SV40 Tag-like nuclear localization signals (NLS) found in the N-terminal third of the protein.
Function

1)
Facilitates the sensitization/resensitization reaction of beta-adrenergic receptors. 2) Scaffolds protein kinase (PK) A, PKC, and SRC. 3) Autoantigen in some cases of myasthenia gravis. 4) Anti-angiogenic factor. The rodent orthologue has been shown to inhibit brain angiogenesis and induce the blood-brain barrier, and to inhibit VEGFmediated metastasis. 5) Metastasis suppressor (see Gelman, 2012) . Many studies show i) AKAP12 downregulation in metastases compared to primary-site tumors, associated with hypermethylation of promoter CpG islands, ii) AKAP12-/-mice are tumor-and metastasis-prone to skin carcinogens, iii) increased spontaneous lymph node metastasis of high-grade prostatic intraepithelial neoplasia in transgenic models, and iv) selective suppression of spontaneous and experimental metastasis following re-expression of rodent Akap12 in MAT-LyLu prostate cancer cells. 6) Effector of Polo-like kinase 1 to regulate cytokinesis. 7) Maintenance of barrier functions such as bloodbrain, blood-retinal barriers and fibrotic scars in CNS repair.
A: Except for testes, most cells express four major isoforms of AKAP12 protein. The 305 kDa isoforms is the myristylated AKAP12alpha whereas the 287 kDa isoforms is AKAP12beta. The 250 kDa and 43 kDa isoforms are proteolytic cleavage products common to the AKAP12alpha and beta isoforms. B: Human AKAP12alpha encodes a 1,780 amino acids full-length protein. The first about 1,000 amino acids of human and rodent AKAP12 share 83% identity followed by about 600 amino acids with less than 20% identity. The N-terminal homology domain (green) shows about 40% identity to the Xgl (Xenopus gravin-like) gene in Xenopus. Both human and rodent AKAP12 share a shorter C-terminal domain containing the PKA-RII binding (AKAP) domain (green box in human AKAP12).
8) Regulation of adhesion, chemotaxis and invasiveness through the control of actin cytoskeletal remodeling.
Homology
Southern blotting analysis as well as analysis of sequenced genomes indicates that vertebrates encode single AKAP12 orthologues, with no gene family members. Thus, the protein diversity of this gene stems from promoter choice, alternative splicing, proteolytic maturation and post-translational modification. AKAP12 has limited sequence homology based on short domains. For example, the C-terminal AKAP domain is homologous to the analogous domain in AKP79. Also, AKAP12 shares some so-called MARCKS protein-like effector domains-positively charged stretches of amino acids involved in plasma membrane targeting.
Mutations
141 mutations (mostly point mutants and some small deletions) have been described in COSMIC, the vast majority of which are found in the major proteincoding exon ("exon 2") ESR1-AKAP12 fusions have been recently described (Ma et al., 2014) in clinical cases of breast cancer. . There are at least 539 single nucleotide polymorphisms (SNP). 59 study datasets for AKAP12 SNPs described in GWAS analyses For example, HGVST779 identifies AKAP12 SNPs associated with chronic myelogenous leukemia. Another study identifies AKAP12 SNPs associated with psychiatric depression (Ripke et al., 2012) . A number of QTLs have been described associated with susceptibility for prostate cancer and insulin sensitivity, and for HDL cholesterol.
AKAP12 is phosphorylated by PLK1 on T766 during metaphase, and shRNa knockdown of AKAP12 leads to cytokinesis failure (Canton et al., 2012) .
Implicated in
Prostate cancer
Note Tumor/metastasis suppressor. Prognosis AKAP12 downregulation correlates with earlier time-to-onset of metastasis (Ko et al., 2014 
Ovarian cancer
Note Possible mediator of drug-resistance. Prognosis AKAP12 upregulation associated with resistance to platins and taxanes (Chappell et al., 2012; Bateman et al., 2015) . Oncogenesis Presumably, the upregulation of AKAP12, and its ability to scaffold kinases such as Src and PKC, and to move them to cellular specific compartments, leads to pathways that facilitate drug resistance, as described in Le and Bast 2011.
Pancreatic cancer
Note Possible tumor/metastasis suppressor. Prognosis Whereas AKAP12 upregulation was noted in human pancreatic cells lines compared to immortalized human pancreatic ductal epithelial cells (Cao et al., Cancer Biol Ther. 2004, 3(11) :1081-9), AKAP12 loss (due to promoter hypermethylation) correlated with increased liver metastasis in pancreatic ductal adenocarcinoma (Mardin et al., 2010 A majority of high-grade (HG) serous ovarian cancer (SOC) patients develop resistant disease despite high initial response rates to platinum/paclitaxel-based chemotherapy. We identified shed/secreted proteins in preclinical models of paclitaxel-resistant human HGSOC models and correlated these candidate proteins with patient outcomes using public data from HGSOC patients. Proteomic analyses of a HGSOC cell line secretome was compared to those from a syngeneic paclitaxel-resistant variant and from a line established from an intrinsically chemorefractory HGSOC patient. Associations between the identified candidate proteins and patient outcome were assessed in a discovery cohort of 545 patients and two validation cohorts totaling 795 independent SOC patients. Among the 81 differentially abundant proteins identified (q < 0.05) from paclitaxel-sensitive vsresistant HGSOC cell secretomes, AKAP12 was verified to be elevated in all models of paclitaxel-resistant HGSOC. Furthermore, elevated AKAP12 transcript expression was associated with worse progression-free and overall survival. Associations with outcome were observed in three independent cohorts and remained significant after adjusted multivariate modeling. We further provide evidence to support that differential gene methylation status is associated with elevated expression of AKAP12 in taxol-resistant ovarian cancer cells and ovarian cancer patient subsets. Elevated expression and shedding/secretion of AKAP12 is characteristic of paclitaxel-resistant HGSOC cells, and elevated AKAP12 transcript expression is a poor prognostic and predictive marker for progression-free and overall survival in SOC patients. [from Bateman et al., 2015] . 
AKAP12 A kinase (PRKA) anchor protein 12
Gastric cancer
Note Possible tumor suppressor. Prognosis Downregulation of AKAP12 due to promoter hypermethylation in gastric cancer (Choi et al., 2004) or in Barrett's esophagus (Jin et al., 2008) . Oncogenesis Presumably, the loss of AKAP12's scaffolding activity for kinases such as Src and PKC result in hyperactivated pathways that contribute to oncogenic transformation, as shown in Su et al., 2010 and Su et al., 2013 .
Liver cancer
Note Possible tumor suppressor.
Prognosis
Downregulation of AKAP12 due to promoter hypermethylation in liver cancer (Goeppert et al., 2010; Hayashi et al., 2012) . Oncogenesis Presumably, the loss of AKAP12's scaffolding activity for kinases such as Src and PKC result in hyperactivated pathways that contribute to oncogenic transformation, as shown in Su et al., 2010 and Su et al., 2013 . Haematol. 2015; 19(9) 
